Investing.com - Protalix reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Protalix announced earnings per share of $-0.070 on revenue of $5.4M. Analysts polled by Investing.com anticipated EPS of $-0.150 on revenue of $5.7M.
Protalix shares are down 73.62% from the beginning of the year , still down 47.50% from its 52 week high of $2.00 set on Monday, April 4, 2022.
Protalix follows other major Healthcare sector earnings this month
Protalix's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar